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JS-K is a nitric oxide (NO)-releasing prodrug of the O2-arylated diazeniumdiolate family that has
demonstrated pronounced cytotoxicity and antitumor properties in a variety of cancer models both
in vitro and in vivo. The current study of the metabolic actions of JS-K was undertaken to investigate
mechanisms of its cytotoxicity. Consistent with model chemical reactions, the activating step in the
metabolism of JS-K in the cell is the dearylation of the diazeniumdiolate by glutathione (GSH) via a
nucleophilic aromatic substitution reaction. The resulting product (CEP/NO anion) spontaneously
hydrolyzes, releasing two equivalents of NO. The GSH/GSSG redox couple is considered to be the
major redox buffer of the cell, helping maintain a reducing environment under basal conditions. We
have quantiﬁed the effects of JS-K on cellular GSH content, and show that JS-K markedly depletes GSH,
due to JS-K’s rapid uptake and cascading release of NO and reactive nitrogen species. The depletion of
GSH results in alterations in the redox potential of the cellular environment, initiating MAPK stress
signaling pathways, and inducing apoptosis. Microarray analysis conﬁrmed signaling gene changes at
the transcriptional level and revealed alteration in the expression of several genes crucial for
maintenance of cellular redox homeostasis, as well as cell proliferation and survival, including MYC.
Pre-treating cells with the known GSH precursor and nucleophilic reducing agent N-acetylcysteine
prevented the signaling events that lead to apoptosis. These data indicate that multiplicative depletion
of the reduced glutathione pool and deregulation of intracellular redox balance are important initial
steps in the mechanism of JS-K’s cytotoxic action.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. er B.V.
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Diazeniumdiolate-based NO-releasing prodrugs are a growing
class of promising cancer therapeutics. O2-Arylated diazeniumdio-
lates release NO upon nucleophilic aromatic substitution reaction
with glutathione (GSH). O2-(2,4-Dinitrophenyl) 1-[(4-ethoxycarbo-
nyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) (structure shown
in Fig. 1) has proven effective for inhibiting growth of cancer cells in
several in vitro and in vivo models [26,27,22,15,17,31]. JS-K is highly
cytotoxic to leukemia and multiple myeloma cell lines and patient-
derived multiple myeloma cells, with IC50 values ranging from 0.2 to
1.2 mM [26,27,15]. Mouse models of leukemia or multiple myeloma
conﬁrmed the effectiveness of JS-K against these blood cancers
in vivo. The prodrug inhibited tumor growth and prolonged survival
in a multiple myeloma xenograft model [15]. Importantly, JS-K
was very effective against multiple myeloma cells resistant to
conventional therapy with dexamethasone, doxyrubicin orD license. 
Fig. 1. Structure of JS-K and mechanism of its activation. The prodrug is activated via nucleophilic aromatic substitution, resulting in generation of NO and its oxidation
products followed by a selection of subsequent reactions leading to decreases in cellular GSH/GSSG ratios.
Fig. 2. GSH-dependent dearylation is a major metabolic pathway of JS-K in the
cell. U937 cells were treated with 5 mM JS-K for 30 min and drug metabolites in
the cell lysate were analyzed by LC/MS. The total ion current chromatogram is
shown. The peak at 6.13 min is DNP-SG, while that at 5.80 min corresponds to S-
(2,4-dinitrophenylated) cysteine. RT¼retention time.
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Furthermore, JS-K appeared to be selectively cytotoxic towards
cancer cells; no signiﬁcant toxicity of the drug was observed in
bone marrow stromal cells isolated from patients, at concentrations
at which it inhibited the proliferation of multiple myeloma cells
[15]. Similar selective toxicity towards cancer cells relative to their
nonmalignant counterparts was observed in breast [18] and renal
cancers [5].
The glutathione (GSH)/glutathione disulﬁde (GSSG) redox
couple plays a central role in cellular protection against genotoxic
agents and oxidants, as well as in the control of the thiol/disulﬁde
redox state, which is essential for redox signaling [12]. GSH is themost abundant cellular antioxidant and is also involved in the
detoxiﬁcation of numerous xenobiotics.
Evidence from many studies suggests that cancer cells are under
increased oxidative stress that is associated with oncogenic transfor-
mation. Oncogene activation or tumor suppressor inactivation in
cancers commonly results in increased generation of reactive oxygen
species (ROS) [24,11,20]. Leukemia cells freshly isolated from blood of
chronic lymphocytic leukemia or hairy-cell leukemia patients showed
increased ROS compared to normal lymphocytes [33,14]. This bio-
chemical property of cancer cells can be exploited for therapeutic
beneﬁts. Induction of oxidative stress may be a promising approach
for cancer therapy, because cancer cells with increased oxidative
stress are likely to be more vulnerable to damage by additional ROS
elicited by exogenous agents. NO is a relatively stable free radical that
does not readily react with most macromolecules in cells. However, it
reacts with oxygen and superoxide, forming reactive nitrogen species
(RNS) that are highly damaging to cells.
In this study we present evidence that treatment of human
leukemia U937 cells with the NO-releasing prodrug JS-K led to the
depletion of GSH, affecting cellular redox potential and triggering
MAPK stress signaling and apoptosis. To characterize further the
biologic potential of JS-K we performed gene expression analysis
using the Affymetrix platform for microarray analysis. This
revealed marked alteration in expression of several genes crucial
for maintenance of cellular redox homeostasis, as well as cell
proliferation and survival.Methods
JS-K synthesis, chemicals and cell culture
JS-K was synthesized as described previously [23]. All other
chemicals were obtained from Sigma (St. Louis, MO). Leukemia
cell line U937 [29] was obtained from the American Type Culture
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supplemented with 10% fetal bovine serum (FBS), glutamine and
penicillin–streptomycin, at 5% CO2, 371 C.
In vitro metabolism of JS-K
Human leukemia U937 cells were seeded in 75-cm2 ﬂasks and
incubated overnight at 371 C, 5% CO2. The cells were treated with
5 mM JS-K and incubated for 10 or 30 min. After treatment, cells
were collected by centrifugation at 800g for 10 min, washed with
phosphate buffered saline (PBS) and collected again. The pellets
were resuspended in 800 mL of 10 mM HCl, then lysed by
successive rounds of freezing and thawing. To the lysate was
added 200 mL of a 5% 5-sulfosalicylic acid solution. The precipitate
was removed by centrifugation at 8000g for 10 min, and the
supernatant was analyzed by LC/MS using a Thermoquest Sur-
veyor HPLC coupled with a Finnigan LCQ Deca mass spectrometer.
Positive ions were generated with an atmospheric pressure
chemical ionization (APCI) source with a capillary voltage of
15 V and a corona discharge of 4 mA. Separations were performed
on an Agilent Eclipse XDB-C18 5-mm 4.6150 mm2 column at a
ﬂow rate of 1 mL/min, under H2O/acetonitrile/0.1% formic acid
gradient conditions. The stability of JS-K in a complete culture
medium (RPMI 1640, 10% FBS) was determined with analogical
extraction and HPLC methods.
Measurement of cellular glutathione content and cellular reduction
potential
U937 cells were cultured at 1106 per mL. Cells were treated
in culture medium with 1 mM JS-K for 1 h or for the time periods
indicated in Fig. 3. After treatment, cells were collected by
centrifugation at 800g for 10 min, washed with phosphate buf-
fered saline and collected again. The pellets were resuspended in
80 mL of 10 mM HCl and lysed by two successive rounds of
freezing and thawing. Twenty microliters of a 5% 5-sulfosalicylic
acid solution were added to the lysate. The precipitate was
removed by centrifugation at 8000g for 10 min, and the super-
natant was analyzed for total GSH content by using a total
glutathione quantiﬁcation kit (Dojindo, Rockville, MD) according
to the manufacturer’s protocol. To measure glutathione disulﬁde
(GSSG) concentration, cells were treated and lysed in accordance
with the procedure above. The lysate was then neutralized withFig. 3. Time course of changes in cellular reduction potential after treating U937
cells with 1 mM JS-K. nnnPo0.0001 and nnPo0.001.0.1 M NaOH and treated with 4-vinylpyridine at a ﬁnal concen-
tration of 50 mM for 30 min, followed by 5,50-dithio-bis(2-nitro-
benzoic acid) assay [9,1]. The results gave the total amounts of
GSH and GSSG present in the cells.
To determine the intracellular concentrations of GSH and GSSG
we ﬁrst measured U937 cell volume. As these cells are spherical,
the diameter of the cell was measured with a confocal microscope
using the built-in measuring tool within the Olympus Fluoview
software. Cells were stained with CellMaskTM Orange plasma
membrane stain at a concentration of 5 mg/mL, following the
manufacturer’s protocol (Invitrogen (Molecular Probes), Carlsbad,
CA). Images were acquired on an Olympus FluoView 1000 con-
focal microscope system with a 40X objective and an excitation
wavelength of 568 nm and emission wavelength of 572 nm. The
average diameter of U937 cells was 19.6870.82 mm with an
average radius of 9.8470.41 mm. The volume of this average
sphere was calculated using the equation V¼(4/3)pr3, and resulted in
an average cell volume of 4.070.5 pL. Molar concentrations of GSH
and GSSG per cell were calculated; then the reduction potential of the
GSH redox couple was calculated using the equation E7.4¼(E1(RT/
nF)log([GSH]2/[GSSG]))þ((pH7.0)(DE/DpH)), where E1 is the elec-
tromotive force at standard conditions, R is the ideal gas constant, T is
temperature in Kelvin, n is the number of electrons transferred in the
redox couple (2e), F is Faraday’s constant, and (DE/DpH) is the
change in reduction potential resulting from a given change in pH at
371 C.
Measurement of mitochondrial membrane potential
U937 cells were seeded on 24-well plates at 2105/well and
allowed to grow for 24 h. The cells were then treated in culture
medium with either vehicle (DMSO) or 1–10 mM JS-K and incu-
bated at 37 1C, 5% CO2 for 30 min. The JC-1 Mitochondrial
Membrane Potential Assay Kit (Cayman Chemical, Ann Arbor,
MI) was used according to the manufacturer’s protocol.
Determination of intracellular reactive oxygen/nitrogen species and
nitric oxide
The intracellular levels of reactive oxygen and nitrogen species
were monitored by the oxidation of the ﬂuorophore 5-(and6)-
chloromethyl-20,70-dichlorodihydroﬂuorescein diacetate (DCFH-
DA) (Invitrogen). U937 cells were incubated with 5 mM DCF-DA
in Hank’s balanced salt solution (HBSS) at 37 1C and 5% CO2 for
30 min. The cells were collected by centrifugation, the HBSS
containing the probe was removed, and the cells were rinsed
with HBSS and resuspended in fresh HBSS. Three mL of cell
suspension was aliquoted into 15-mL test tubes followed by
addition of JS-K or DMSO as a control. After 60 min of incubation
at 371 C, 20,70-dichloroﬂuorescein (DCF) ﬂuorescence was mea-
sured by using a PerkinElmer Life and Analytical Sciences (Wal-
tham, MA) LS50B luminescence spectrometer with the excitation
source at 488 nm and emission at 530 nm.
The intracellular level of nitric oxide after JS-K treatment was
estimated using the NO-sensitive ﬂuorophore 4-amino-5-methy-
lamino-20,70-diﬂuoroﬂuorescein (DAF-FM) diacetate (Invitrogen).
This reagent hydrolyzes after being taken up by the cell, where it
reacts with nitrosating agents formed upon 1-electron oxidation
of NO to generate a ﬂuorescent species whose intensity is taken as
a measure of intracellular NO. Cells were loaded with 2.5 mM
DAF-FM diacetate in HBSS at 37 1C and 5% CO2. After 30 min of
incubation the cells were rinsed with HBSS to remove excess
probe, resuspended in fresh HBSS, and treated with JS-K at 1 mM
ﬁnal concentration. After 60-min incubation the ﬂuorescence of
the benzotriazole derivative formed on DAF-FM’s reaction with
aerobic NO was analyzed by using a PerkinElmer Life and
Table 1
Alterations in cellular redox potential.
NAC Treatment GSH (mM) GSSG
(mM)
Redox potential
(mV)
DE
(mV)
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excitation source at 495 nm and emission at 515 nm.
Immunoblotting
Western blot analysis was performed as previously described
[17]. Primary antibodies for phospho-p38, p38, phospho-SAPK/
JNK, SAPK/JNK, phospho-ATF2, phospho-c-jun, c-jun, caspases 3,
7, and 8, cytochrome c, PARP and cleaved PARP, c-myc (Cell
Signaling Technology, Danvers, MA) and ATF3 (Santa Cruz Bio-
technology, Santa Cruz, CA) were used.
Microarray analysis
RNA extraction and transcriptome proﬁling. Total RNAs from
three independent cultures for each treatment time point or
control were extracted using TRIzol reagent (Invitrogen) follow-
ing the manufacturer’s protocol. RNA qualities were checked by
the 260 nm/280 nm optical density ratio and Bioanalyzer 2100
(Agilent, Santa Clara, CA) prior to transcriptome analyses. Micro-
array experiments were performed using Affymetrix (Santa Clara,
CA) Human U133 Plus 2.0 GeneChip by the Laboratory of
Molecular Technology, Frederick National Laboratory for Cancer
Research, Frederick, MD, USA. cRNA probe synthesis, hybridiza-
tion, and scanning of arrays followed the manufacturers’ default
protocols. Probe signal values and detection calls were deter-
mined using Affymetrix GeneChip Command and Console Soft-
ware. Chip-to-Chip variations were normalized by the Robust
Multichip Average normalization algorithm.
Multivariate analysis. GeneChip data were exported to BRB-
ArrayTools, an open source microarray statistical analysis plug-in
for the Microsoft Excel software (Microsoft Professional 2003).
The non-supervised hierarchical clustering approach was chosen
for the data set exploration.
Class comparison analysis. The class comparison module in BRB-
ArrayTools was utilized to identify differentially and statistically
signiﬁcantly expressed genes between sample groups. Microarray
data from different comparison pairs were subjected to a two-sample
t-test (with random variance model). Type I error correction was
applied to all pairwise comparisons. Pairwise analysis was performed
using control vs. treated using a fold cut-off of 43.
Pathway analysis. Gene lists winnowed from the multivariate
analyses were exported to the Ingenuity Pathway Analysis (IPA)
web portal (http://www.ingenuity.com) for functional pathway
analysis.
Statistical analysis
All experiments were performed at least three times, each
time at least in triplicate. Results are presented as averages7SE.
Statistical tests of chemical and protein results were carried out
using GraphPad Instat version 3.00 (GraphPad Software, San
Diego, CA). Pairwise comparisons included the t test, with the
Welch correction or application of the Mann–Whitney test as
appropriate. Signiﬁcance of correlations was assessed by the
Pearson linear correlation or the Spearman test as appropriate.None DMSO 3.4370.14 0.2070.01 227.6
JS-K 1 mM 2.7070.16 0.2170.01 219.1
JS-K 4 mM 1.4670.16 0.3170.02 197.7 29.9
0.1 mM DMSO 4.3070.15 0.1870.01 233.8
JS-K 1 mM 3.7570.23 0.2470.01 227.2
JS-K 4 mM 2.5570.22 0.3770.04 209.8 24.0
1 mM DMSO 6.7470.18 0.1670.01 247.6
JS-K 1 mM 6.0170.26 0.1870.01 243.6
JS-K 4 mM 5.4070.26 0.2570.02 236.8 10.8Results
GSH-dependent dearylation is a major metabolic pathway for JS-K in
the cell
Cellular redox potential is largely controlled by GSH, which
accounts for more than 90% of cellular non-protein thiols [7]. JS-K
was designed to release NO upon nucleophilic attack by freethiols (particularly GSH). The ﬁrst step in the metabolism of JS-K
in the cell is the dearylation of the diazeniumdiolate by GSH via a
nucleophilic aromatic substitution reaction, liberating the ionic
diazeniumdiolate moiety CEP/NO, which spontaneously hydro-
lyzes, releasing NO (Fig. 1). Subsequent oxidation products of the
NO can react with additional equivalents of GSH. A consequence
of this metabolism is a rapid depletion of cellular GSH concurrent
with a rise in oxidized glutathione (GSSG) (Fig. 1).
JS-K is relatively stable in complete (RPMI 1640, 10% FBS) cell
culture medium, with a half-life of about 5 h. However, it is
rapidly and completely metabolized by the cells. Liquid chroma-
tography/mass spectrometry (LC/MS) analysis revealed that
30 min after addition of JS-K to the cell culture the parent
compound is not detectable in the lysate; we have found
glutathione and cysteine adducts derived from JS-K (Fig. 2), the
latter presumably resulting from further metabolism of the
glutathione conjugate. The parent compound was also not
detected after shorter treatment (10 min); however, in this case
only the glutathione adduct was seen (data not shown).
JS-K has a major impact on cellular redox status
We quantiﬁed GSH and GSSG levels in the U937 leukemia cell
line, which grows in suspension as spherical cells. As described
under Materials and Methods, we determined the average cell
volume to be 4.070.5 pL, and measured total amounts of GSH
and GSSG. Concentrations per cell and the reduction potential of
the GSH redox couple were calculated. Table 1 shows changes in
cellular GSH/GSSG concentrations and reduction potential in
U937 leukemia cells after JS-K treatment. One-hour treatment
with JS-K led to a decrease in total GSH concentration, a decrease
in GSH/GSSG ratio, and a rise in reduction potential.
A noteworthy feature of the data in Table 1 is the extent to which
low concentrations of JS-K in the medium can generate major
changes in cellular GSH/GSSG levels. For example, 1 mM JS-K in the
medium dropped the intracellular GSH level by 730 mM, while 4 mM
JS-K consumed 1970 mM GSH and increased GSSG by 110 mM.
Although the depletion of hundreds of micromoles of GSH by low
mM concentrations of JS-K may seem counter-intuitive, a closer look
at the stoichiometry provides a rationale. Assuming that the number
of moles of JS-K is equally dispersed amongst the cells in suspension,
1.5 fmol and 6 fmol are delivered per cell when JS-K is added to the
medium at 1 mM and 4 mM concentrations, respectively. Upon
metabolism and NO production, a signiﬁcant portion of the 13.7 fmol
of GSH per cell is consumed, 2.9 fmol from 1 mM treatment and
7.9 fmol from 4 mM treatment, translating to an observable decrease
in the cellular GSH concentration.
U937 cells were pretreated with N-acetylcysteine (NAC), a
precursor for GSH synthesis and a nucleophilic reducing agent, to
determine whether it attenuates the disruption of redox balance.
Indeed, pretreatment with NAC prevented the depletion of GSH
A.E. Maciag et al. / Redox Biology 1 (2013) 115–124 119associated with JS-K treatment alone and partially prevented the
rise in reduction potential (Table 1). Time-dependent study
revealed that the rise in reduction potential was signiﬁcant within
minutes of treatment with 1 mM JS-K (Fig. 3), consistent with
rapid reaction of the prodrug with GSH. We have shown pre-
viously that the rate of reaction with GSH is important for
anticancer efﬁcacy of aryl-diazeniumdiolate-based NO-releasing
prodrugs [17,19].
Depletion of cellular antioxidant defenses allows for the
generation of signiﬁcant quantities of ROS, which have been
suggested to induce apoptosis [16]. The release of NO from JS-K
in the cells was conﬁrmed by DAF ﬂuorescence assay (Fig. 4(A)).
There was also an increase in DCFH-DA-reactive material, sug-
gesting an increase in oxidizing equivalents. One-hour treatment
with 0.5 mM JS-K resulted in an increase in DCF ﬂuorescence,
which was more pronounced at higher concentrations of the
prodrug (Fig. 4(B)). It may be noted that DCFH-DA reacts with
reactive nitrogen species such as peroxynitrite ([10,13]).
Oxidative stress leads to activation of cellular stress signaling and
apoptosis
Oxidative stress is widely observed to activate the stress
kinases p38 and SAPK/JNK pathways, leading to activation of
stress-response genes. Phosphorylation of p38 was very rapidlyFig. 4. (A) Intracellular NO release in U937 cells after JS-K treatment measured as
DAF ﬂuorescence. (B) Intracellular ROS/RNS level after JS-K treatment measured as
DCF ﬂuorescence. Cells were loaded with the probe for 30 min, followed by 1-h
treatment with JS-K at concentrations indicated on the graph. A representative
experiment is shown (n¼6). nnnPo0.0001, by two-tailed paired t test, compared
with cells treated with DMSO only.induced by JS-K. A strong signal was observed as soon as 5 min
after treatment with JS-K was initiated and it continued for
several hours; at the 16-h time point the signal was signiﬁcantly
reduced (Fig. 5(A)). Importantly, pretreatment with NAC encum-
bered phosphorylation of p38, suggesting that redox imbalance/
oxidative stress is a triggering mechanism in this pathway’s
activation (Fig. 5(B)). Phosphorylation of the p38 downstream
target ATF2 exhibited the same pattern. SAPK/JNK activation was
detected slightly later, about 1 h after JS-K treatment was
initiated. Phosphorylation of its downstream target, transcription
factor c-jun, was observed after 1 h as well.
We have shown previously that upregulation of activating
transcription factor 3 (ATF3) is required for cell killing by aryl-
diazeniumdiolate-based NO-releasing prodrugs in non-small cell
lung cancer (NSCLC) cells [17]. Here we observed a signiﬁcant
increase in ATF3 protein in the leukemia cells as well, starting 4 h
after JS-K treatment was initiated.
To determine whether the induction of ROS/RNS and stress
signaling was associated with cell death, cells were treated with
JS-K and then analyzed by Western blot for markers of apoptosis.
Apoptosis was activated early, initially through the extrinsic
pathway, as evidenced by caspase-8 activation within 2 h of
treatment with 1 mM JS-K (Fig. 6(A)). Cleaved effector caspase-7
and cleaved PARP signals were also observed within 2 h
(Fig. 6(A)).
JS-K-induced U937 cell death is blocked by NAC
As shown in Table 1, pretreatment with NAC increased the
basal levels of GSH, and diminished the rise in reduction poten-
tial. Moreover, NAC blocked JS-K-induced U937 cell apoptosis
(Fig. 6(B)). U937 cells (5105/mL) were pretreated with 0.1 or
1 mM NAC for 16 h, followed by 3 h with 1 mM JS-K. Pretreatment
with NAC inhibited activation of apoptosis, as evidenced by
diminished cleavage of caspases-8 and -3.
Loss of mitochondrial membrane potential after JS-K treatment
Fig. 7(A) shows loss of mitochondrial membrane potential in
U937 cells after 4 h incubation with 1 mM JS-K; there was even
more signiﬁcant loss of this membrane potential with 5 mM JS-K
(Fig. 7(A)). A similar effect of JS-K was observed previously in
H1703 NSCLC cells after 1 h of incubation with 1 mM drug [17].
One-hour treatment did not result in loss of mitochondrial
membrane potential in U937 cells, suggesting that the sequence
of events could be cell-type speciﬁc, and that in U937 cells
apoptosis by an extrinsic pathway precedes involvement of
mitochondria in the cell death pathway. Collapse of mitochon-
drial membrane potential has been shown to represent a stage of
cell death that is already irreversible [32]. Mitochondrial apopto-
sis was also activated, as evidenced by presence of cytochrome c
in cytosol after 4 h treatment with JS-K (Fig. 7(B)).
Microarray analysis
To provide an assessment of transcripts and pathways altered
by JS-K, treated cells were subjected to microarray analysis.
Treatment with JS-K resulted in differential expression of 1800
transcripts, suggesting an extensive response to JS-K. Marked up-
regulation of expression of JUN and ATF3 (Table 2) conﬁrms the
protein results shown in Fig. 5 and indicates regulation of these at
the mRNA level. The c-MYC oncogene was downregulated pro-
gressively with time (Table 2). We conﬁrmed downregulation of
the protein level of this short-lived transcription factor by
Western blot. As shown in Fig. 8(B), c-myc protein expression
Fig. 5. Activation of stress signaling pathways in U937 cells after JS-K treatment. (A) JS-K very rapidly induced phosphorylation of p38 and its downstream target ATF2.
Phosphorylation of SAPK/JNK and its downstream target c-jun, as well as upregulation of c-jun protein level, were observed later, after 1-h treatment with the drug.
Signiﬁcant upregulation of ATF3 protein level occurs after 4 h with the drug. Representative Western blots (left panel), and percentage of control (at zero time point)
quantitative densitometric values (mean7SD) from 2 or 3 independent experiments (right panel) are shown. a Po0.001; b Po0.01, compared to time zero.
(B) Pretreatment with 1 mM NAC for 16 h prevented p38 phosphorylation after 30 min treatment with 1 mM JS-K. Representative Western blot (left panel) and percentage
of untreated control densitometric values (mean7SD from 3 independent experiments) (right panel) are shown. Phosphorylation of p38 was signiﬁcantly reduced by
pretreatment with NAC (a Po0.001, by two-tailed paired t test, compared with cells treated with JS-K).
A.E. Maciag et al. / Redox Biology 1 (2013) 115–124120was downregulated rapidly, with complete loss of signal after 2 h
of treatment with JS-K.
As expected, the transcriptome from treated cells was
enriched in genes implicated in the response to oxidative
stress. NF-E2-related factor 2 (NFE2L2, Nrf2) is considered as
one of the major transcription factors activated in response to
oxidative stress. Upon oxidative stress Nrf2 translocates to the
nucleus and upon heterodimerization with other transcription
factors (e.g., JunD, ATF4, small MAFs) transactivates the anti-
oxidant response elements of many cytoprotective genes, as
well as Nrf2 itself. In our study, NFE2L2 transcript was upre-
gulated 1.4-, 1.6-, and 5-fold at 1.5, 4 and 24 h, respectively.
Similarly, JunD was upregulated 1.8-, 4.8-, and 3-fold at the
same time points. Expression of many Nrf2-regulated geneswas altered. NQO1 (NADPH: quinone oxidoreductase 1), a
major detoxiﬁcation enzyme, was upregulated 2, 2.6 and 4-fold,
at 1.5, 4 and 24 h, respectively. Antioxidant HMOX1 (heme
oxygenase 1) was upregulated 5-fold at 1.5 h and 31-fold at 4 h,
then its transcript level decreased. Transcript of the rate-
limiting enzyme in glutathione synthesis, GCLM (glutamate-
cysteine ligase, modiﬁer subunit) was upregulated 2-fold at
1.5 h and 4-fold at 4 h. Similarly, SLC7A11, a cystine/glutamate
antiporter, was upregulated over 2-fold at 1.5 h and over 7-fold
at 4 h. These changes appear to be triggered by depletion of
GSH from the cell in a cellular attempt to restore its supply.
Complete microarray data have been deposited on the GEO
website http://www.ncbi.nlm.nih.gov/geo (GEO Accession num-
ber GSE42344).
Fig. 6. Treatment with JS-K induced the extrinsic apoptosis pathway in U937 cells. (A) Cleavage of caspase-8 and the effector caspase-7, as well as PARP, was seen within
2 h after addition of the drug. Representative Western blots (left panel), and percentage of control (at zero time point) quantitative densitometric values (mean7SD) from
2 or 3 independent experiments (right panel) are shown. F.L. – full length caspase. *** Po0.001, compared to 0-h control. (B) Pretreatment with NAC (0.1 or 1 mM) for 16 h
encumbered activation of apoptosis. Cleaved caspase-8 and -3 signals are signiﬁcantly diminished in cells pretreated with NAC. Representative Western blots (left panel)
and percentage of untreated control quantitative densitometric values (mean7SD, right panel) are shown; F.L.—full length caspase 8; Cl.—cleaved fragment (43 kDa);
*** Po0.001, compared to JS-K-treated cells.
Fig. 7. Treatment with JS-K induced the intrinsic apoptosis pathway in U937 cells. (A) Mitochondrial membrane potential (DCm) was analyzed using JC-1 mitochondrial
membrane dye. U937 cells were treated with DMSO (control) or JS-K (1 or 5 mM) for 4 h. The drug caused an increase in the green (JC-1 monomers) and decrease in the red
ﬂuorescence (JC-1 aggregates) indicative of loss of DCm. Ratio of JC-1 (red to green) was calculated. nnPo0.001, nnnPo0.0001, by two-tailed paired t-test, compared to
control cells, treated with DMSO. (B) Cytochrome c release to cytosol was observed 4 h after JS-K treatment. Representative Western blot and percentage of control
quantitative densitometric values (mean7SD) are shown. nnnPo0.0001, by two-tailed paired t-test, compared to control cells, treated with DMSO.
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Oxidative stress occurs when there is an imbalance between
the rates of ROS generation and removal by scavenging mechan-
isms. Glutathione is a ubiquitous cellular thiol. Its reduced form(GSH) and oxidized form (GSSG) constitute the major thiol redox
system in cells, and proper GSH/GSSG redox balance is crucial for
cell function.
Activation of the nitric oxide-releasing prodrug JS-K to release
NO through nucleophilic aromatic substitution depletes cells of
Table 2
Most signiﬁcant alterations in gene expression after JS-K treatment.
Gene symbol Description Fold change
90 min 4 h 24 h
Genes most upregulated
IL8 Interleukin 8 38.73 82.10 39.46
JUN Jun oncogene 26.40 17.73 14.42
TRIB1 Tribbles homolog 1 (Drosophila) 15.84 36.92 35.84
PRDM1 PR domain containing 1, with ZNF domain 15.06 11.81 15.23
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 13.06 12.03 100.96
MAFB v-maf Musculoaponeurotic ﬁbrosarcoma oncogene homolog B (avian) 12.81 22.96 46.63
FZD7 Frizzled homolog 7 (Drosophila) 11.02 9.37 6.11
EGR3 Early growth response 3 10.52 5.09 1.49
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 9.78 2.34 2.15
ATF3 Activating transcription factor 3 9.35 15.24 31.36
FABP4 Fatty acid binding protein 4, adipocyte 8.20 8.36 28.29
MXD1 MAX dimerization protein 1 7.21 6.81 3.83
KLF6 Kruppel-like factor 6 6.65 7.44 8.05
EMP1 Epithelial membrane protein 1 5.52 20.24 305.46
FOXO3 Forkhead box O3 5.46 3.18 2.04
HMOX1 Heme oxygenase (decycling) 1 5.30 31.54 3.40
C5AR1 Complement component 5a receptor 1 5.04 21.11 116.57
IER3 Immediate early response 3 3.93 14.05 71.61
PALLD Palladin, cytoskeletal associated protein 1.09 11.10 22.60
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 2.83 10.68 46.40
TREM1 Triggering receptor expressed on myeloid cells 1 3.59 10.04 49.94
ADFP Adipose differentiation-related protein 4.26 9.96 9.03
FPR1 Formyl peptide receptor 1 2.14 9.34 55.67
GPR34 G protein-coupled receptor 34 1.72 1.83 60.34
TDO2 Tryptophan 2,3-dioxygenase 1.05 1.15 46.91
CREB5 cAMP responsive element binding protein 5 1.05 3.21 44.56
CCL3 Chemokine (C-C motif) ligand 3 1.02 8.96 41.19
PHLDA1 Pleckstrin homology-like domain, family A, member 1 1.85 5.22 35.93
TRIB1 Tribbles homolog 1 (Drosophila) 15.84 36.92 35.84
CD86 CD86 molecule 1.01 1.03 26.48
Genes most downregulated
ACSM3 Acyl-CoA synthetase medium-chain family member 3 7.33 7.76 7.92
FDFT1 Farnesyl-diphosphate farnesyltransferase 1 6.38 6.79 7.04
SCD Stearoyl-CoA desaturase (delta-9-desaturase) 6.09 9.73 6.17
SC4MOL Sterol-C4-methyl oxidase-like 6.01 10.93 4.10
INSIG1 Insulin induced gene 1 5.60 7.86 5.00
SNRPN Small nuclear ribonucleoprotein polypeptide N 5.27 5.30 5.13
ACSS2 Acyl-CoA synthetase short-chain family member 2 4.73 3.46 2.26
GSTA4 Glutathione S-transferase A4 4.36 3.28 3.06
MARS2 Methionyl-tRNA synthetase 2, mitochondrial 1.08 12.24 24.75
HMGCS1 3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 4.30 12.16 7.13
DPP7 Dipeptidyl-peptidase 7 3.96 8.04 12.50
PTCD2 Pentatricopeptide repeat domain 2 2.33 7.49 7.83
POLR1B Polymerase (RNA) I polypeptide B, 128 kDa 1.08 7.43 13.86
MYC v-myc Myelocytomatosis viral oncogene homolog (avian) 2.79 6.88 19.79
POLR1B Polymerase (RNA) I polypeptide B, 128 kDa 1.08 7.43 13.86
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and formation of GSSG. We have for the ﬁrst time quantiﬁed loss
of GSH and increase in GSSG as a function of treatment of cancer
cells with an arylated diazeniumdiolate prodrug. Our results
demonstrate that depletion of the cellular glutathione pool is an
important ﬁrst step in the cytotoxic action of JS-K. Thanks to the
rapid and complete uptake of the micromolar levels of JS-K from
the culture medium, it was on scale to effectively impact milli-
molar concentrations of GSH in the cell. Depletion of GSH as a
therapeutic strategy in sensitizing cancer cells to radiation ther-
apy has been demonstrated [8]. Cancer cells depleted of GSH
through inhibition of its synthesis with buthionine sulfoximine
(BSO) were much more sensitive to the effects of irradiation.
It will be noted that JS-K is a particularly efﬁcient consumer of
GSH, with each molecule imported into the cell being capable of
destroying multiple reducing species through GSH-arylation and
oxidation of NO to form reactive nitrogen species (Fig. 1). That
such signiﬁcant consumption of GSH by JS-K was indeedoperative in these cells was conﬁrmed in our experiments. As
stated in the Results, the number of moles of JS-K delivered per
cell is in the same scale as the number of moles of GSH. Each mole
of JS-K irreversibly arylates a mole of GSH, resulting in release of
two moles of NO, the oxidation products of which are capable of
consuming more reduced equivalents of GSH (Fig. 1). This con-
sumption of GSH results in a rise in the steady-state level of ROS/
RNS, further consuming GSH, with a concurrent increase in GSSG
(Table 1). Additional ROS likely are produced as a result of the
damage to cellular catalytic systems (e.g., mitochondria), and this
ROS causes further depletion of GSH, an additional 6 fmol of GSH
per cell from a 24 h treatment with1 mM JS-K. Export of GSSG
from the cell may also contribute to depletion of cellular GSH and
rise in reduction potential, as GSSG is a known endogenous
substrate for multidrug resistance proteins [3].
SAPK/JNK and p38 stress kinases are important mediators of
cell death signaling resulting from a variety of cellular stresses,
including ROS/RNS. We have reported previously that SAPK/JNK
Fig. 8. JS-K inhibited c-myc oncogene expression in U937 cells. (A) Downregula-
tion of MYC-dependent transcripts after JS-K treatment. Based upon the Ingenuity
Knowledge Database, IPA pathway analysis revealed an interactive gene network
around MYC. The network indicated that MYC is upstream of many important
genes and may play a critical role in different pathways. Data processed for IPA
analysis were based upon the differentially and statistically signiﬁcant expressed
gene set at the 24-h time point. (B) Downregulation of c-myc protein expression
after JS-K treatment. Representative blot and percentage of control quantitative
densitometric values (mean7SD) are shown. a, Po0.001; b, Po0.01, compared to
0-h control cells. Actin serves as a loading control.
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in vitro and in xenografts [17]. Involvement of the SAPK/JNK
pathway in activation of apoptotic cell death has been reported
[30], as well as its involvement in ATF3 induction [4]. Kiziltepe
and colleagues have shown that activation of SAPK/JNK in multi-
ple myeloma cells in response to JS-K is a critical step in the
apoptotic pathway’s activation, and that pretreatment with JNK
inhibitor II rescued multiple myeloma cells from apoptosis.
In leukemia U937 cells, however, we observed rapid activation
of p38, preceding SAPK/JNK phosphorylation. Phosphorylation
and activation of p38 by peroxynitrite have been reported in
neuroblastoma cells [21]. Decrease in p38 phosphorylation uponJS-K treatment has been noted in breast cancer cells [28]. The
involvement of ROS in JS-K activity was further illustrated by
experiments showing that the reducing agent NAC protected
against p38 activation and apoptotic cell death.
Microarray analysis provided some useful additional informa-
tion about this leukemia cell model. Increases in c-jun and ATF3
protein were preceded by changes in gene expression. A number
of genes presented marked up- or down-regulation. These
included cancer-related genes such as MAF and FOS oncogenes
that could be targeted for combination therapy along with JS-K.
Similarly, several antioxidant factors were upregulated, which, if
individually targeted, could increase the effectiveness of JS-K even
further.
Progressive and marked downregulation of the proto-
oncogene c-MYC revealed by microarray, and conﬁrmed by
immunoblot, is especially notable, in view of its frequent involve-
ment in hematopoietic cancers. In various lymphomas and
leukemias it inhibits differentiation and functions as a leukemo-
genic protein. C-MYC gene ampliﬁcation and translocation, result-
ing in its deregulation, have been observed in Burkitt’s lymphoma
and acute lymphoblastic leukemia ([6]; [2]). Inactivation of the
MYC oncogene has also been shown sufﬁcient to induce regres-
sion of invasive liver cancers [25].
In summary, we have shown that in U937 leukemia cells a
micromolar concentration of the NO-donor prodrug JS-K is
sufﬁcient to induce major depletion in GSH, due to its rapid,
complete uptake from the culture media and subsequent cascade
of reactions with NO-derived species. Marked progressive
increase in cellular ROS/RNS and change in cellular reduction
potential result, followed by cellular stress signaling, downregu-
lation of c-myc, and initiation of apoptosis. This mechanistic
information may be useful for enhancement of the efﬁcacy of
JS-K and similar drugs.Acknowledgments
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